PMID- 15766414
OWN - NLM
STAT- MEDLINE
DCOM- 20090424
LR  - 20181201
IS  - 1007-8738 (Print)
IS  - 1007-8738 (Linking)
VI  - 21
IP  - 2
DP  - 2005 Mar
TI  - [Identification of a novel HLA-A2-restrictive CTL epitope of an ovary 
      cancer-associated antigen OVA66].
PG  - 233-6, 242
AB  - AIM: To identify a novel HLA-A2-restrictive CTL epitope of an ovary 
      cancer-associated antigen OVA66. METHODS: Dendritic cells (DCs), induced from 
      peripheral blood mononuclear cells(PBMCs) by cytokines, were confirmed by 
      morphological observation and FACS. Mature DCs were pulsed with each of the two 
      synthesized peptides which were selected as possible CTL epitopes by software 
      analysis. The pulsed DCs were used to stimulate autologous CD8+ T cells from an 
      HLA-A2+ healthy donor. One week later, the peptides-pulsed autologous PBMCs were 
      used to stimulate the CD8+ T cells for another 3 times at weekly intervals. The 
      stimulated CD8+ T cells were used as CTLs. The cytotoxicity of CTLs to target 
      cells was detected by lactate dehydrogenase (LDH) release assay and the number of 
      T cells secreting antigen-specific IFN-gamma in CTLs was analyzed by 
      enzyme-linked immunospot assay (ELISPOT). RESULTS: The results of morphology 
      observation and FACS indicated that mature DCs were induced from PBMCs. Of the 
      two peptides, peptide L235(FLPDHINIV) induced peptide-specific CD8+ T cells that 
      lysed HLA-A2+ T2 cells pulsed with L235 and OVA66+/HLA-A2+ SW480 cells. Compared 
      with control peptide, L235 increased the number of IFN-gamma producing T cells. 
      CONCLUSION: This novel OVA66-derived CTL epitope L235 can induce 
      HLA-A2-restrictive CTL response, which lays the foundation for preparation of 
      tumor-specific peptide vaccine.
FAU - Jin, Shu
AU  - Jin S
AD  - Shanghai Institute of Immunology, Shanghai Second Medical University, Shanghai 
      200025, China. jinshushu@sina.com
FAU - Wang, Ying
AU  - Wang Y
FAU - Wang, Shu-jun
AU  - Wang SJ
FAU - Zhang, Hui-zhen
AU  - Zhang HZ
FAU - Li, Mei-xing
AU  - Li MX
FAU - Chen, Ying
AU  - Chen Y
FAU - Ge, Hai-liang
AU  - Ge HL
LA  - chi
PT  - Journal Article
PL  - China
TA  - Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi
JT  - Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular 
      immunology
JID - 101139110
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Cancer Vaccines)
RN  - 0 (Epitopes, T-Lymphocyte)
RN  - 0 (HLA-A2 Antigen)
RN  - 0 (Peptides)
RN  - 82115-62-6 (Interferon-gamma)
SB  - IM
MH  - Amino Acid Sequence
MH  - Animals
MH  - Antigens, Neoplasm/*immunology
MH  - Cancer Vaccines/immunology
MH  - Cell Proliferation
MH  - Dendritic Cells/immunology
MH  - Epitopes, T-Lymphocyte/*analysis/*immunology
MH  - Female
MH  - Flow Cytometry
MH  - HLA-A2 Antigen/*immunology
MH  - Humans
MH  - Interferon-gamma/metabolism
MH  - Mice
MH  - Ovarian Neoplasms/*immunology
MH  - Peptides/chemistry/immunology
MH  - T-Lymphocytes, Cytotoxic/*immunology/metabolism/pathology
EDAT- 2005/03/16 09:00
MHDA- 2009/04/25 09:00
CRDT- 2005/03/16 09:00
PHST- 2005/03/16 09:00 [pubmed]
PHST- 2009/04/25 09:00 [medline]
PHST- 2005/03/16 09:00 [entrez]
PST - ppublish
SO  - Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2005 Mar;21(2):233-6, 242.